Kirsten P J Smits1, Grigory Sidorenkov1, Henk J G Bilo2, Margriet Bouma3, Frans J van Ittersum4, Jaco Voorham1, Gerjan Navis5, Petra Denig1. 1. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 2. Diabetes Centre, Isala Clinics, Zwolle, The Netherlands. 3. Dutch College of General Practitioners (NHG), Utrecht, The Netherlands. 4. Department of Nephrology, VU University Medical Center Amsterdam, Amsterdam, The Netherlands. 5. Department of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Abstract
BACKGROUND: Quality assessment is a key element for improving the quality of care. Currently, a comprehensive indicator set for measuring the quality of medication treatment in patients with chronic kidney disease (CKD) is lacking. Our aim was to develop and validate a set of prescribing quality indicators (PQIs) for CKD care, and to test the feasibility of applying this set in practice. METHODS: Potential indicators were based on clinical practice guidelines and evaluated using the RAND/UCLA Appropriateness Method. This is a structured process in which an expert panel assesses the validity of the indicators. Feasibility was tested in a Dutch primary care database including >4500 diabetes patients with CKD. RESULTS: An initial list of 22 PQIs was assessed by 12 experts. After changing 10 PQIs, adding 2 and rejecting 8, a final list of 16 indicators was accepted by the expert panel as valid. These PQIs focused on the treatment of hypertension, albuminuria, mineral and bone disorder, statin prescribing and possible unsafe medication. The indicators were successfully applied to measure treatment quality in the primary care database, but for some indicators the number of eligible patients was too small for reliable calculation. Results showed that there was room for improvement in the treatment quality of this population. CONCLUSIONS: We developed a set of 16 PQIs for measuring the quality of treatment in CKD patients, which had sufficient content and face validity as well as operational feasibility. These PQIs can be used to point out priority areas for improvement.
BACKGROUND: Quality assessment is a key element for improving the quality of care. Currently, a comprehensive indicator set for measuring the quality of medication treatment in patients with chronic kidney disease (CKD) is lacking. Our aim was to develop and validate a set of prescribing quality indicators (PQIs) for CKD care, and to test the feasibility of applying this set in practice. METHODS: Potential indicators were based on clinical practice guidelines and evaluated using the RAND/UCLA Appropriateness Method. This is a structured process in which an expert panel assesses the validity of the indicators. Feasibility was tested in a Dutch primary care database including >4500 diabetespatients with CKD. RESULTS: An initial list of 22 PQIs was assessed by 12 experts. After changing 10 PQIs, adding 2 and rejecting 8, a final list of 16 indicators was accepted by the expert panel as valid. These PQIs focused on the treatment of hypertension, albuminuria, mineral and bone disorder, statin prescribing and possible unsafe medication. The indicators were successfully applied to measure treatment quality in the primary care database, but for some indicators the number of eligible patients was too small for reliable calculation. Results showed that there was room for improvement in the treatment quality of this population. CONCLUSIONS: We developed a set of 16 PQIs for measuring the quality of treatment in CKDpatients, which had sufficient content and face validity as well as operational feasibility. These PQIs can be used to point out priority areas for improvement.
Authors: Lavanya Bathini; Racquel Jandoc; Paul Kuwornu; Eric McArthur; Matthew A Weir; Manish M Sood; Marisa Battistella; Flory T Muanda; Aiden Liu; Arsh K Jain; Amit X Garg Journal: Clin J Am Soc Nephrol Date: 2019-01-10 Impact factor: 8.237
Authors: Veronika J Wirtz; Hans V Hogerzeil; Andrew L Gray; Maryam Bigdeli; Cornelis P de Joncheere; Margaret A Ewen; Martha Gyansa-Lutterodt; Sun Jing; Vera L Luiza; Regina M Mbindyo; Helene Möller; Corrina Moucheraud; Bernard Pécoul; Lembit Rägo; Arash Rashidian; Dennis Ross-Degnan; Peter N Stephens; Yot Teerawattananon; Ellen F M 't Hoen; Anita K Wagner; Prashant Yadav; Michael R Reich Journal: Lancet Date: 2016-11-08 Impact factor: 79.321
Authors: Danielle M Nash; Scott Brimble; Maureen Markle-Reid; Eric McArthur; Karen Tu; Gihad E Nesrallah; Allan Grill; Amit X Garg Journal: Can J Kidney Health Dis Date: 2017-05-23
Authors: Woldesellassie M Bezabhe; Alex Kitsos; Timothy Saunder; Gregory M Peterson; Luke R Bereznicki; Barbara C Wimmer; Matthew Jose; Jan Radford Journal: J Clin Med Date: 2020-03-13 Impact factor: 4.241